EUnetHTA Joint Action 3 (2016-20) JA3-WP4
2017 - Web Page

Please click on the link(s) below to access the published assessment(s). When there is no link available, the assessment is still ongoing. Please note that the dates may be subject to change.

For a complete list of all assessments in previous JAs and the present JA, see Joint Assessments

EUnetHTA unique identifier: all EUnetHTA assessments are given a unique identifier according to a specific scheme in order to allow easy identification of the assessments. Unique identifiers are assigned by the EUnetHTA work package leads or co-leads according to the start date of the assessments and need to be indicated on all assessment related documents.

There is no continuous numbering of assessments in the different EUnetHTA Joint Actions (JA2 and JA3). Therefore, please see description of unique identifiers below.

EUnetHTA Joint Action 2

Pilot ID (rapid REA):

WP5-SA-0 (Pharmaceutical Technologies: ranging from 1 until 6)

WP5-SB-00 (Other Technologies: ranging from 11 until 16)

Core HTAs: no unique identifier used

EUnetHTA Joint Action 3

Project ID: [PT/OT][CA/JA][00] e.g. PTJA01

• Pharmaceutical Technologies (PT)

• Other Technologies (OT)

• Collaborative Assessment (CA)

• Joint Assessment (JA)

• 2 digit number (according to start date of assessment)

Please note that there is separate counting for pharmaceutical technologies and other technologies. However, collaborative assessments and joint assessments are counted together (e.g. OTCA6, OTCA7, OTJA8…).

Project IDTitle1st AuthorsCo-AuthorsDedicated ReviewersProject StartPublication of Project PlanPublication of Final Assessment
Other Technologies
OTCA01Wearable cardioverter-defibrillator (WCD) therapy
in primary and secondary prevention of sudden cardiac arrest in patients at risk
LBI-HTAAAZIQWIG, AVALIA-T01.05.201618.08.201630.11.2016
OTCA02Antibacterial-coated sutures versus non-antibacterial-coated sutures for the prevention of abdominal, superficial and deep, surgical site infection (SSI)AAZNSPHMPDBSUKL, NIPN/OGYEI,
VASPVT, SNHTA, IQWIG
25.08.201606.10.201627.04.2017
OTCA03Screening of fetal aneuploidies whereby non-invasive prenatal test (NIPT)Avalia-tRER

MIDT, SNHTA, NIPN, IQWIG


Observer: EOPYY

01.11.2016

22.03.201731.01.2018
OTCA04Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancerZINKCELBI-HTA, HAS01.12.201610.11.201729.12.2017
OTCA05Repetitive transcranial magnetic stimulation for treatment-resistant major depressionLBI-HTAOstebaKCE, FUNCANIS05.12.201721.04.201721.04.2017
OTCA06Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical riskAGENASNIPHNOSNHTA, OCSC, HIQA, KCE, REGIONE VENETO08.05.201708.11.201731.01.2018
OTCA07Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard ultrasound phacoemulsification cataract surgeryRERGOG, HAS

KCE, Osteba, SECS/FUNCANIS and AQUAS

Observer: VASPVT

01.09.2017

11.12.201730.06.2018
Pharmaceutical technologies
PTJA01Midostaurin for the indication of Acute Myeloid LeukaemiaFIMEANOMA

TLV, ZIN, HAS, NICE, AEMPS

Information retrieval: IQWIG

Observer: SUKL, SU, EOPPY, SESCS

31.01.2017

20.06.201708.11.2017
PTJA02Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib treatmentHASINFARMED

AAZ, SNHTA, FIMEA, LBI, NIPN, AETSA

Observer: EOF, EKAPTY

25.02.2017

10.07.201725.10.2017
PTJA03Alecensa as monotherapy is indicated for the first-line treatment of adult patients with ALK+ advanced NSCLCTLVHVB, AAZ

NICE, Regione Veneto, Uniba, AETSA, NIPN

Observer: MOH MALTA

26.07.2017

20.10.201824.01.2018

Abbreviations: OT-other technologies, PT-pharmaceutical technologies, CA-collaborative assessment, JA-joint assessment